Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
| Autor: | Ahn, Inhye E., Brander, Danielle M., Ren, Yue, Zhou, Yinglu, Tyekucheva, Svitlana, Walker, Heather A., Black, Robert, Montegaard, Josie, Alencar, Alvaro, Shune, Leyla, Omaira, Mohammad, Jacobson, Caron A., Armand, Philippe, Ng, Samuel Y., Crombie, Jennifer, Fisher, David C., LaCasce, Ann S., Arnason, Jon, Hochberg, Ephraim P., Takvorian, Ronald W., Abramson, Jeremy S., Brown, Jennifer R., Davids, Matthew S. |
|---|---|
| Zdroj: | In Blood Advances 27 February 2024 8(4):832-841 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|